Contraline Secures $92.5M to Push Its Male Birth Control Candidates Forward
Contraline raised $92.5 million in new funding to advance its two male contraceptive candidates, including a once-daily topical gel and an implantable option.
Trial Data Shows ‘IUD for Men’ Is Effective for 2 Years
Contraline released promising new trial data showing that its male contraceptive gel has demonstrated safety and efficacy in the first two trial participants to reach the two-year mark. The company is aiming to earn the product’s FDA approval by the end of 2028, according to CEO Kevin Eisenfrats.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
The Future of Birth Control: No Hormones, More Options for Men
The advancement, adoption of, and access to these options – regardless of age, geography, and financial considerations – requires the support of the scientific community, drug developers, funders, regulatory agencies, insurers, and lawmakers to make the concept of a hormone-free future a reality.
Trial Data Looks Promising for ‘IUD For Men’
Contraline released promising data from the clinical trial it’s conducting to test the efficacy of Adam, its male birth control product. The nonhormonal gel seems to be doing a good job of blocking the flow of sperm to the vas deferens, and no serious adverse events have been reported.
One Step Closer to ‘IUD For Men’: Doctors Inject First Humans with Male Contraceptive Gel
Medical device company Contraline became the first to implant a hydrogel-based male contraceptive gel into humans in a clinical trial. Implanted during a noninvasive 10-minute office procedure, the gel promises to block the flow of sperm to the vas deferens. If proven safe and effective, it could become the first nonhormonal, reversible contraceptive for men on the market.